This project aims to investigate the molecular drivers of malignancy and invasiveness in cutaneous squamous cell carcinoma (cSCC) and Morbus Bowen using advanced single-cell RNA sequencing (scRNA-seq) techniques. cSCC is the most common skin cancer, with a significant increase in incidence, particularly among high-risk populations such as organ transplant recipients. Understanding the mechanisms that underlie the aggressive nature of cSCC is crucial for developing targeted therapies and improving patient outcomes. We will conduct scRNA-seq on tumor samples from patients with cSCC and Morbus Bowen, a non-invasive form of skin cancer. By comparing the gene expression profiles of invasive and non-invasive tumors, we aim to identify specific mRNA and non-coding RNA (ncRNA) signatures and other molecular alterations that drive tumor progression. This comparative analysis will provide insights into the unique pathways that contribute to the invasive properties of cSCC, as well as the factors that restrict invasion in Morbus Bowen. The project will utilize both computational and experimental approaches to analyze the data generated from scRNA-seq. We will employ bioinformatics tools to assess cellular heterogeneity and identify key regulatory networks involved in tumor invasion and metastasis. Additionally, we will validate our findings through functional assays, including in vitro and in vivo models, to elucidate the role of identified ncRNAs in promoting or inhibiting tumor growth and invasiveness. The anticipated outcomes of this research include the identification of novel biomarkers for cSCC, which may serve as therapeutic targets or prognostic indicators. Furthermore, the project seeks to enhance our understanding of the tumor microenvironment in cSCC, paving the way for innovative RNA-based therapies and personalized treatment strategies. By uncovering the complex interactions between ncRNAs and other molecular players in cSCC and Morbus Bowen, this study aims to contribute significantly to the field of cancer research and improve the clinical management of patients affected by these malignancies. The results will not only advance our scientific knowledge but also have the potential to lead to more effective and targeted interventions for high-risk skin cancer patients.